HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the year ended December 31, 2006. Product sales increased by 3.0% and amounted to $437,440 for 2006, compared to $424,506 for 2005. Nymox reported a net loss of $4,893,685, or $0.18 per share for the year ended December 31, 2006, compared to $3,584,528, or $0.14 per share for 2005. 63% of the increase in net loss was attributable to accounting requirements for stock option compensation. The weighted, diluted average number of common shares at December 31, 2006 was 27,711,981, compared to 26,103,704 at December 31, 2005. Nymox currently has $11.0 million in financing available from its most recent financing.
